8-K: MoonLake Sonelokimab Phase 3 HS Trials Show Mixed Week 16 Results

MoonLake Immunotherapeutics announced week 16 results from its Phase 3 VELA-1 and VELA-2 trials for sonelokimab in moderate-to-severe hidradenitis suppurativa, with VELA-2 missing its primary endpoint under the composite strategy.

Summary

• The combined Phase 3 VELA program demonstrated clinically meaningful and statistically significant improvement across all primary and key secondary endpoints (p<0.001) using both pre-specified statistical strategies.
• VELA-1 achieved statistical significance for all primary and key secondary endpoints, with a HiSCR75 delta to placebo of 17% (p<0.001) using both pre-specified strategies.
• VELA-2 did not achieve statistical significance for its week 16 primary endpoint (HiSCR75, delta to placebo of 9%, p=0.053) using the composite strategy, primarily due to a higher-than-expected placebo response rate of 25.6%.
• Using the pre-specified treatment policy strategy, VELA-2 did achieve a statistically significant HiSCR75 at week 16 (35.9% vs. 25.6% placebo, p=0.033), and all key secondary endpoints were met.
• Sonelokimab maintained a favorable safety profile consistent with previous studies, with no new safety signals, including the absence of suicidal ideation and behavior, hepatic events, IBD, non-infectious diarrhea, MACE, and Eczema/Dermatitis.
• The VELA program will continue to its pre-specified week 52 readout, and the company will engage with regulatory authorities to confirm the path to registration for sonelokimab in HS.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the combined VELA program and VELA-1 showed strong positive results, the failure of VELA-2 to meet its primary endpoint under the composite strategy due to a high placebo response introduces a significant regulatory hurdle and uncertainty, tempering overall enthusiasm despite the positive safety profile and consistent sonelokimab performance across both trials using the treatment policy strategy.

Positives

• The combined VELA program showed statistically significant improvements across all primary and key secondary endpoints (p<0.001) using both analysis strategies.
• VELA-1 achieved statistical significance for all primary and key secondary endpoints, with a HiSCR75 delta to placebo of 17% (p<0.001).
• Sonelokimab demonstrated a favorable safety profile with no new safety signals, consistent with prior studies, and an absence of key events of interest.
• Statistically significant HiSCR75 responses were observed as early as week 4 in both studies, indicating rapid onset of action.
• Sonelokimab showed consistent response rates between VELA-1 (34.8% HiSCR75) and VELA-2 (35.9% HiSCR75) using the treatment policy strategy.
• Significant improvements were observed in patient-reported outcomes (PROs) such as pain reduction (around 30% of patients), HiSQOL score (p<0.001), and DLQI (almost 60% of patients achieved meaningful improvement).
• The convenient subcutaneous dosing scheme (every other week for induction, then monthly for maintenance) is a potential advantage.

Negatives

• VELA-2 failed to achieve statistical significance for its primary endpoint (HiSCR75) at week 16 (p=0.053) when analyzed using the composite strategy, which is the primary statistical analysis.
• The placebo response rate in VELA-2 (25.6%) was higher than expected, impacting the statistical significance of the primary endpoint under the composite strategy.

Risks

• Regulatory authorities may not agree that the two statistical strategies, when reviewed together, provide substantial evidence of efficacy for the VELA program, particularly given VELA-2's failure on the primary endpoint under the composite strategy.
• Interim data from the VELA trials may not be consistent with the final 52-week data.
• Difficulty in enrolling patients in ongoing or future clinical trials, including VELA-TEEN and IZAR program.
• Reliance on third parties to conduct and support preclinical studies and clinical trials.
• General business risks associated with a clinical-stage biotechnology company and its limited operating history.
• State and federal healthcare reform measures could result in reduced demand for product candidates.

Future Outlook

The company will now seek to confirm the path to registration in HS with appropriate regulatory authorities. The VELA program will progress to its pre-specified week 52 readout. Other clinical studies with sonelokimab, including Phase 3 VELA-TEEN in adolescent HS, Phase 3 IZAR program and Phase 2 P-OLARIS in psoriatic arthritis, Phase 2 LEDA in palmoplantar pustulosis, and Phase 2 S-OLARIS in axial spondyloarthritis, continue as planned and are expected to support a catalyst-rich roadmap with several key readouts anticipated in Q4 2025, Q1 2026, and H1 2026.

Management Comments

• Prof. Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: 'We are encouraged by the results of VELA-1, which follow the expected performance of sonelokimab in all the important metrics for patients and treating physicians.'
• Prof. Kristian Reich stated: 'The higher-than-expected placebo response rate in VELA-2 is disappointing but we are encouraged by the consistent performance of sonelokimab arms across all endpoints in both studies.'
• Prof. Kristian Reich added: 'We are pleased to see a favorable safety profile consistent with previous studies, with no new safety signals.'
• Prof. Kristian Reich concluded: 'We believe that this, together with the convenient dosing, the efficacy data in the lesion-based metrics and the patient reported outcomes, shows the potential for a promising profile of sonelokimab in HS. Patients with HS are in desperate need of new treatment options and we remain committed to our path forward in HS.'

Industry Context

Hidradenitis suppurativa (HS) is a severely debilitating chronic skin condition affecting an estimated 2% of the population, with a significant unmet need for new treatment options. The market opportunity for HS treatments is projected to reach $15 billion by 2035. There is increasing scientific evidence supporting IL-17Aand IL-17F-mediated inflammation as a key driver of HS pathogenesis. Sonelokimab, a Nanobody, inhibits IL-17A and IL-17F, positioning it within a class of therapies targeting this pathway for inflammatory diseases.

Comparison to Industry Standards

• The VELA program utilized HiSCR75 as the primary endpoint, which is a higher clinical response level compared to the HiSCR50 measure often used in other clinical trials for HS, setting a landmark milestone.
• The placebo response rate in VELA-1 of 17.5% at week 16 was within the historical Phase 3 range of 13% to 18% for HS trials.
• Sonelokimab's mechanism of action, inhibiting IL-17A and IL-17F, targets a pathway increasingly recognized as a key driver in HS pathogenesis, similar to other IL-17 inhibitors in the market or development for inflammatory conditions.

Stakeholder Impact

• Shareholders: Mixed results introduce uncertainty regarding the regulatory path for sonelokimab in HS, potentially impacting stock valuation.
• Patients with HS: Sonelokimab continues to show potential as a new treatment option, offering clinically meaningful benefits and a favorable safety profile, but regulatory approval timeline is now less certain.
• Regulatory bodies: Will need to evaluate the two statistical analysis strategies and the impact of the high placebo response in VELA-2 to determine the path to Biologics License Application submission.

Next Steps

• Discuss interim results with appropriate regulatory authorities to confirm the path to registration for sonelokimab in HS.
• Continue the VELA program to its pre-specified week 52 readout.
• Proceed with the Phase 2 LEDA trial in PPP, with primary endpoint readout expected Q4 2025.
• Proceed with the Phase 2 S-OLARIS trial in axSpA, with primary endpoint readout expected Q1 2026.
• Proceed with the Phase 3 VELA-TEEN trial in adolescent HS, with primary endpoint readout expected H1 2026.
• Proceed with the Phase 3 IZAR program in PsA, with primary endpoint readout expected H1 2026.

Key Dates

Recommendation

The recommendation is 'hold' due to the mixed results from the Phase 3 VELA program. While VELA-1 and the combined data showed strong statistical significance and a favorable safety profile, the failure of VELA-2 to meet its primary endpoint under the composite strategy (the primary analysis) creates a significant regulatory uncertainty. This introduces a material risk to the drug's path to market for HS, despite the positive outcomes under the treatment policy strategy and the consistent performance of sonelokimab itself. Investors should await further clarity from regulatory discussions and the 52-week data before making a definitive investment decision, as the stock could experience volatility based on these developments.

Keywords

MoonLake Immunotherapeutics, sonelokimab, hidradenitis suppurativa, HS, Phase 3, VELA trials, clinical trial results, Nanobody, IL-17A/F inhibitor, biotechnology, dermatology, inflammatory disease